Source comparison
DSIP vs Epithalon: Research Comparison
Both peptides serve distinct research purposes with minimal overlap in biological targets or study applications. Primary Mechanism Modulates delta-wave sleep architecture through hypothalamic GABA-ergic pathways; reduces stress-induced cortisol elevation by 31
This comparison does not assign a generated winner or score.
- Both peptides serve distinct research purposes with minimal overlap in biological targets or study applications.
- Primary Mechanism
- Modulates delta-wave sleep architecture through hypothalamic GABA-ergic pathways; reduces stress-induced cortisol elevation by 31–38% without affecting basal HPA axis function
- Activates telomerase enzyme (TERT) increasing telomere length by average 582 base pairs per cycle; restores age-related pineal gland function and melatonin secretion patterns
- Non-overlapping mechanisms. Selection depends entirely on research question: circadian/stress biology (DSIP) vs cellular senescence/aging (Epithalon)
- Molecular Structure
- 9-amino-acid peptide (Tyr-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu), 849 Da molecular weight, crosses blood-brain barrier via passive diffusion, half-life 15–20 minutes with 6–8 hour downstream effects
- 4-amino-acid peptide (Ala-Glu-Asp-Gly), 390 Da molecular weight, 85–90% subcutaneous bioavailability, effects persist 8–12 days post-administration
- DSIP requires precise timing relative to circadian phase; Epithalon's extended duration suits cyclical protocols (10 days on, 90 days off)
- Research Applications
- Sleep architecture studies, stress response mechanisms, HPA axis regulation, circadian biology, NREM sleep enhancement (22–27% increase in slow-wave duration)
- Telomere biology, cellular senescence, age-related physiological decline, pineal function restoration, endothelial aging, cardiovascular gerontology
- Complementary rather than competing applications. Some aging research protocols combine both to address pineal decline and circadian disruption simultaneously
- Typical Dosing Range
- 5–10 mcg/kg body weight, single daily administration 30–60 minutes before rest phase, effects diminish with continuous use (tolerance develops within 14–21 days)
- 5–10mg daily for 10–20 consecutive days, administered as quarterly cycles, no tolerance observed with cyclical protocol, telomerase activation persists between cycles
- DSIP best suited for acute or intermittent protocols; Epithalon's cyclical structure better matches longitudinal aging research designs
- Post-Reconstitution Stability
- 14 days at 2–8°C with 95%+ potency (bacteriostatic water 1–2mg/mL), drops to 85% by day 21 and below 70% by day 28, glycine residues vulnerable to peptidase activity
- 28 days at 2–8°C with <5% potency loss, resistant to enzymatic degradation, tolerates higher concentrations (5mg/mL), can use sterile saline for short-term storage
- Epithalon's stability advantage reduces preparation frequency for extended studies. DSIP requires fresh reconstitution every 2 weeks
- Primary Study Endpoints
- Polysomnography delta-wave amplitude, sleep latency, cortisol response curves, HPA axis reactivity, GABA receptor binding assays, stress-induced gastric ulceration
- Telomere length (qPCR), telomerase activity (TRAP assay), cellular senescence markers (SA-β-gal, p16/p21 expression), melatonin secretion patterns, endothelial NO production
- Objective measurement approaches differ entirely. Neurophysiology and endocrinology for DSIP, molecular gerontology and chronobiology for Epithalon